pargyline has been researched along with Muscular Dystrophy in 2 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sorato, E | 1 |
| Menazza, S | 1 |
| Zulian, A | 1 |
| Sabatelli, P | 1 |
| Gualandi, F | 1 |
| Merlini, L | 1 |
| Bonaldo, P | 1 |
| Canton, M | 1 |
| Bernardi, P | 1 |
| Di Lisa, F | 1 |
| Yu, MK | 1 |
| Wright, TL | 1 |
| Dettbarn, WD | 1 |
| Olson, WH | 1 |
2 other studies available for pargyline and Muscular Dystrophy
| Article | Year |
|---|---|
Monoamine oxidase inhibition prevents mitochondrial dysfunction and apoptosis in myoblasts from patients with collagen VI myopathies.
Topics: Adult; Apoptosis; Cells, Cultured; Child; Child, Preschool; Collagen Type VI; Humans; Hydrogen Perox | 2014 |
Pargyline-induced myopathy with histochemical characteristics of Duchenne muscular dystrophy.
Topics: Acetylcholine; Adenosine Triphosphatases; Animals; Aorta, Abdominal; Biogenic Amines; Disease Models | 1974 |